The company is significantly improved its development of the innovative solution for amyloid heart disease, employing Attruby. Preliminary patient data reveals promising improvements for patients diagnosed BridgeBio by the debilitating disease. This emphasis highlights the company’s dedication to addressing unmet patient demands in the cardiology